Skip to main content
Toggle navigation
Search
Home
Browse by Speaker
Home
Browse by Speaker
Browse by Speaker
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
K
Kaiser, Martin
The Institute of Cancer Research; Royal Marsden Hospital
Optimal treatment for high risk mm
Location: Hall FG
Martin Kaiser
Kapoor, Prashant
Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA
Meet the Experts: Waldenström's
Location: Room 716A
Prashant Kapoor
Kastritis, Efstathios
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
Meet the Experts: Amyloidosis
Location: Room 716B
Efstathios Kastritis
Kaufman, Jonathan
Winship Cancer Institute of Emory University
Debate on ADCs, Bispecifics or CART
Location: Hall FG
Jonathan Kaufman
(OA-59) The Anti-BCMA Antibody-Drug Conjugate HDP-101 with a Novel Amanitin Payload Shows Promising Data in Relapsed/Refractory Multiple Myeloma in a Phase 1/2a Clinical Trial as it Advances into Cohort 7
Location: Room 701
Jonathan Kaufman
Kim, Sungjae
Cancer Program, Broad Institute
(OA-43) Monoclonal Gammopathy of Indeterminate Potential (MGIP) as an Early and Premalignant Stage in the Evolution Toward Hematological Malignancies
Location: Room 718
Sungjae Kim
King, Tracy
Institute of Haematology, Royal Prince Alfred Hospital The University of Sydney
9th Nursing & Allied Health Symposium: Session 2: Enhanced Supportive Care Modalities
Location: Room 501
Tracy King
Optimising patient outcomes through best supportive care: Case-based moderated panel discussion
Location: Room 501
Tracy King
Klarica, Daniela
Alfred Health
(NSO-03) Reframing Myeloma Supportive Care: Nurse-led Leadership to Improve Patient Outcomes
Location: Room 501
Daniela Klarica
Kostic, Ana
Arcellx, Inc.
Anitocabtagene Autoleucel: Innovation in BCMA-Targeting Therapeutics
Location: Hall FG
Ana Kostic
Krishnan, Amrita
City of Hope Orange County
Immunotherapy vs conventional treatment at the time of the first relapse
Location: Hall FG
Amrita Krishnan
Kristinsson, Sigurdur
University of Iceland
What else is important in the transition from Smoldering to MM?
Location: Hall FG
Sigurdur Kristinsson
Kroog, Glenn
Regeneron Pharmaceuticals, Inc
Next-Generation Immunotherapies for Relapsed/Refractory Multiple Myeloma (RRMM): Integrating Costimulatory Bispecific Antibody (bsAb) Signaling
Location: Hall FG
Glenn Kroog
Krüger, Josefine
Columbia University Irving Medical Center
GCK inhibition as a new therapeutical approach in RASMut myeloma and possible strategy to overcome therapy resistance
Location: Hall FG
Josefine Krüger
Trainee Forum and Networking Reception
Location: Room 501
Josefine Krüger
Kumar, Shaji
Mayo Clinic, Rochester, MN, US
Managing myeloma with limited resources - challenges and opportunities
Location: Delta Hotel
Shaji Kumar
Q&A
Location: Hall FG
Shaji Kumar
Updated IMWG/IMS Uniform Response Criteria
Location: Hall FG
Shaji Kumar
